

NCE funding for **CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CDRD)**

\$23 million for 2008-18

CANADIAN MODEL SPEEDS DEVELOPMENT OF NEW DRUGS

The opportunity

Developing new drugs is a long, complex and expensive process. In Canada, one of the greatest challenges facing the development and commercialization of novel health technologies coming out of Canada's universities and research hospitals is a dearth of venture capital. A Vancouver-headquartered, nationally-mandated Centre of Excellence for Commercialization and Research (CECR) has made great strides in pre-validating and de-risking many of these publicly funded discoveries to create viable investment opportunities for the private sector. This innovative model is accelerating the commercialization of medical innovations that will improve health care delivery and patient care in Canada and abroad.

CDRD at a glance

NCE program

Centres of Excellence for
Commercialization and Research

Number of partners

35

Partner contributions

\$85.9 million

Headquarters

Vancouver, British Columbia

President and CEO



Gordon C. McCauley

Board chair



Don Avison
Former President, University Presidents'
Council of BC



How CDRD is seizing the opportunity

The Centre for Drug Research and Development (CDRD) is the only fully-integrated centre of its kind in Canada — and one of a handful in the world — with the full expertise and infrastructure to source, evaluate, develop and commercialize both small molecule and biologic innovative technologies across therapeutic areas. In addition to being a technology incubator and creating spin-off companies based on promising academic research from across the country, CDRD is also an accelerator that supports scale-up companies in moving discoveries through pre-clinical stages.

Among the results

- CDRD has evaluated more than 1,400 technologies for their commercial and therapeutic potential. Of those, 269 were incubated within CDRD and 58 were successfully advanced towards commercialization, generating 72 patents.
- CDRD has spun-off seven new companies, including Zucara Therapeutics, which is developing a novel technology to prevent hypoglycemia in patients with diabetes, and Sitka Biopharma Inc., which is improving chemotherapy drug absorption with its patented polymeric nanoparticle platform technology.
- CDRD spin-off company Kairos Therapeutics merged with Zymeworks Inc., creating one of the industry's leading biotherapeutics companies that is developing antibody drug conjugates for improved oncology treatments.
- CDRD expanded its global industry partnership portfolio with the addition of AstraZeneca. The agreement provides unique resources that will allow CDRD to provide validation and screening for novel drug targets.

Learn more about CDRD:
www.cdrd.ca

cdrd The Centre
for Drug Research
and Development



Government of Canada
Networks of Centres
of Excellence

Gouvernement du Canada
Réseaux de centres
d'excellence

www.nce-rce.gc.ca

Canada